Table 4 Comparison between the group with LV subclinical dysfunction and the group without LV subclinical dysfunction. Values are reported as mean (SD) and percentage % with number “n”
From: Right ventricle involvement in patients with breast cancer treated with chemotherapy
Baseline (T0) | Patients with subclinical dysfunction (relative reduction GLS > 15%) n = 27 | NO subclinical dysfunction n = 51 | p-value |
|---|---|---|---|
Age | 55 (9.7) | 54.7 (10.7) | 0.9 |
Cigarette smoke % (n) | 41% (11) | 45% (23) | 0.7 |
Hypertension % (n) | 41% (11) | 27% (14) | 0.2 |
Type 2 diabetes % (n) | 7% (2) | 4% (2) | 0.5 |
Dyslipidemia % (n) | 26% (7) | 4% (2) | 0.003 |
Obesity % (n) | 11% (3) | 10% (5) | 0.8 |
Family History of CVD % (n) | 26% (7) | 12% (6) | 0.1 |
ACE-I % (n) | 19% (5) | 6% (3) | 0.08 |
ARBs % (n) | 11% (3) | 4% (2) | 0.2 |
Beta-blockers % (n) | 19% (5) | 6% (3) | 0.08 |
Diuretics % (n) | 11% (3) | 4% (2) | 0.2 |
Calcium antagonists % (n) | 7% (2) | 0 | - |
Statins % (n) | 15% (4) | 4% (2) | 0.08 |
Acetylsalicylic acid % (n) | 4% (1) | 6% (3) | 0.7 |
RV-FWLS (%) | -27.2 (4.0) | -25.5 (3.3) | 0.0430 |
RV GLS (%) | -22.4 (2.8) | -21.9 (2.1) | 0.3577 |
RV-3DEF (%) | 63.2 (3.7) | 63.6 (4.0) | 0.6567 |
TAPSE (%) | 22.7 (2.7) | 22.1 (2.9) | 0.2551 |
RV-S’ (%) | 13.6 (1.7) | 13.5 (2.4) | 0.5695 |
FAC (%) | 50.2 (9.0) | 49.6 (4.1) | 0.5298 |